natgillin/translations-raw huggingface dataset:
Administration of Lutathera and conduct of the procedure Lutathera is administered directly into a vein. 
Lutathera se primjenjuje izravno u venu.
Gastrointestinal tube insertion Stent placement Abscess drainage Bone marrow harvest Polypectomy 
Umetanje gastrointestinalne cijevi Postavljanje stenta Drenaža apscesa
Refractory cytopenia with unilineage dysplasia Nephrogenic anaemia Bone marrow failure Thrombocytopenic purpura 
Refraktorna citopenija s displazijom jedne krvotvorne loze Nefrogena anemija Zatajenje koštane srži
Storage of the vial 
Korištenje zahoda
Hyperparathyroidism 
Sekundarna hipotireoza
Hindgut 
Nuspojave
Lethargy Syncope 
Otopina aminokiselina
What Lutathera contains - The active substance is lutetium (177Lu) oxodotreotide. 
- Djelatna tvar je lutecijev (177Lu) oksodotreotid.
- If you get any side effects, talk to your nuclear medicine doctor. 
- Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika specijalista nuklearne medicine.
Osmolarity 
Osmolarnost
Specification of commercially available amino acid solutions Characteristic 
Opis odabranih nuspojava Toksičnost za koštanu srž
BATCH NUMBER Batch: 
BROJ SERIJE Serija:
Fertility 
Hematohezija
Acute kidney injury Haematuria Renal failure Proteinuria 
Akutna ozljeda bubrega Hematurija
Upper Large Intestine Wall Heart Wall 
Stijenka gornjeg dijela debelog crijeva
Breasts 
Parestezija
• The infusion set should be connected to the bag of sodium chloride 9 mg/mL (0.9%) solution for injection and pre-filled by opening the clamp. 
• Komplet za infuziju trebao bi biti povezan s vrećicom otopine natrijeva klorida 9 mg/mL
Dizziness Dysgeusia Headache10 
Omaglica Disgeuzija Glavobolja10 Letargija Sinkopa
Contact your nuclear medicine doctor if you have any questions. 
Ako imate pitanja, obratite se svojemu liječniku specijalistu nuklearne medicine.
Major or some specific adverse reactions to Lutathera. 
ili 4. eventualno povezana s lijekom Lutathera.
− Amino acid solution bag(s) 
− Vrećica/e s otopinom aminokiselina − Antiemetici
Haematocrit decreased Protein urine 
Zatajenje bubrega Proteinurija
Osteogenic Cells Skin 
Crvena koštana srž Osteogene stanice Koža
Taste disturbances, 
NAVOĐENJE DJELATNE (IH) TVARI
Do not give this medicine to children (under 12 years of age) because it does not work. 
Nemojte dati ovaj lijek djeci (mlađoj od 12 godina) jer ne djeluje.
Always take this medicine exactly as your doctor or pharmacist has told you. 
Uvijek uzimajte ovaj lijek točno onako kako su Vam rekli Vaš liječnik ili ljekarnik.
Contact your doctor immediately if you experience: 
Odmah se obratite svom liječniku ako primijetite:
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet:
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na klopidogrel ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
The active metabolite is formed mostly by 
Aktivni metabolit nastaje većinom putem
The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment. 
Studija ACTIVE-A uključivala je bolesnike koji nisu mogli primati terapiju VKA zbog toga što nisu bili podobni ili nisu željeli primati terapiju.
Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Odmah se morate javiti liječniku ili u najbliži odjel hitne medicinske pomoći zbog povećanog rizika od krvarenja.
• Adults and elderly (over 65 years) Clopidogrel should be given as a single daily dose of 75 mg. 
• Odrasli i starije osobe (u dobi iznad 65 godina) Klopidogrel se daje u jednokratnoj dnevnoj dozi od 75 mg.
You should take Clopidogrel HCS for as long as your doctor continues to prescribe it. 
Lijek Klopidogrel HCS trebate uzimati sve dok Vam ga liječnik propisuje.
Some other medicines may influence the use of Clopidogrel HCS or vice versa. 
Neki lijekovi mogu utjecati na djelovanje lijeka Klopidogrel HCS i obratno.
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
<1/100); rijetke (≥1/10 000, <1/1000); vrlo rijetke (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
-4.0%; CI: -22.5 to 11.7 [p=0.639]). 
ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p=0,639]).
• Your doctor may order blood tests. 
• liječnik će možda odrediti da Vam se naprave pretrage krvi.
Date of first authorisation: 28 October 2010 Date of latest renewal: 16 June 2015 
Datum posljednje obnove odobrenja: 16. lipnja 2015
What Clopidogrel HCS is and what it is used for 
Što je Klopidogrel HCS i za što se koristi
In the long-term safety follow-up of this study, 26 patients with the shunt still in place at one year of age received clopidogrel up to 18 months of age. 
dugotrajnoj nastavnoj studiji o sigurnosti primjene, 26 bolesnika koji su još uvijek imali šant nakon godinu dana starosti, primali su klopidogrel do 18 mjeseci starosti.
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction. 
U podskupini s infarktom miokarda većina je bolesnika prvih nekoliko dana nakon akutnog infarkta miokarda primala
- a planned surgery (including dental) in the next seven days. 
- nedavnog kirurškog zahvata (uključujući stomatološke zahvate), - planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
Clopidogrel HCS contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel HCS sadrži klopidogrel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
While you are taking Clopidogrel HCS: 
Dok uzimate Klopidogrel HCS:
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8. 
Ostali aleli povezani sa odsutnim ili smanjenim metabolizmom uključuju CYP2C19*4, *5, *6, *7 i *8, ali oni su manje zastupljeni.
What Clopidogrel HCS is and what it is used for What you need to know before you take Clopidogrel HCS How to take Clopidogrel HCS Possible side effects 
Što je Klopidogrel HCS i za što se koristi Što morate znati prije nego počnete uzmati Klopidogrel HCS Kako uzimati Klopidogrel HCS
CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4. 
CYP2C19 uz sudjelovanje nekoliko drugih CYP enzima, uključujući CYP1A2, CYP2B6 i CYP3A4.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
Nije bilo dokaza o kancerogenim učincima kad se klopidogrel davao miševima 78 tjedana i štakorima 104 tjedna u dozama do 77 mg/kg na dan (što predstavlja barem 25 puta veću izloženost nego u ljudi koji primaju kliničku dozu od 75 mg/dan).
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC04. 
Farmakoterapijska skupina: inhibitori agregacije trombocita izuzev heparina, ATK oznaka: B01AC04.
How to store Clopidogrel HCS Contents of the pack and other information 
Kako čuvati Klopidogrel HCS Sadržaj pakiranja i druge informacije
What Clopidogrel HCS looks like and contents of the pack 
Kako Klopidogrel HCS izgleda i sadržaj pakiranja
Your doctor should have prescribed Clopidogrel HCS plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
Liječnik Vam treba propisati Klopidogrel HCS i acetilsalicilatnu kiselinu ako ne možete uzimati oralne antikoagulanse te nemate rizik od velikog krvarenja.
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet. 
U relativnoj studiji bioraspoloživosti lijeka u odraslih, konstituirana otopina klopidogrela pokazala je sličan raspon i neznatno veću brzinu apsorpcije glavnog cirkulirajućeg (inaktivnog) metabolita, u usporedbi s tabletom.
For the 28x1 tablets pack size, you can check the day on which you last took a tablet of Clopidogrel HCS by referring to the calendar printed on the blister. 
Na pakiranju od 28x1 tableta možete pomoću kalendara otisnutog na blisteru provjeriti dan kada ste zadnji put uzeli tabletu Klopidogrel HCS.
Clopidogrel HCS 75 mg 
Klopidogrel HCS 75 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKO PAKIRANJE
It also contains hydrogenated castor oil. 
Također sadrži: hidrogenirano ricinusovo ulje.
HCS bvba, H. Kennisstraat 53, B 2650 Edegem, Belgium 
Kennisstraat 53, B 2650 Edegem, Belgija
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of food. 
Žutica; jaka bol u trbuhu s bolovima u leđima ili bez njih; vrućica, teškoće pri disanju, ponekad povezane s kašljem; generalizirane alergijske reakcije (primjerice, sveukupni osjećaj vrućine s iznenadnom općom nelagodom do nesvjestice); oticanje u ustima; mjehurići na koži; kožne alergijske reakcije; upala u usnoj šupljini (stomatitis); pad krvnoga tlaka; zbunjenost; halucinacije; bol u zglobovima; bol u mišićima, poremećaj okusa ili gubitak osjeta okusa hrane.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Sigurnost primjene i djelotvornost klopidogrela procijenjena je u 5 dvostrukoslijepih studija koje su uključivale više od 88 000 bolesnika: studija CAPRIE, u kojoj su uspoređivani klopidogrel i ASK, te studije CURE, CLARITY, COMMIT i ACTIVE-A, u kojima je uspoređivano djelovanje klopidogrela u odnosu na placebo, a obje su terapije davane u kombinaciji s ASK i drugom standardnom terapijom.
The ACTIVE-W and ACTIVE-A studies, separate trials in the ACTIVE program, included patients with atrial fibrillation (AF) who had at least one risk factor for vascular events. 
Fibrilacija atrija Studije ACTIVE-W i ACTIVE-A, zasebna ispitivanja u programu ACTIVE, uključivale su bolesnike s fibrilacijom atrija (FA) koji su imali najmanje jedan faktor rizika za krvožilne događaje.
If you become pregnant while taking Clopidogrel HCS, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Ako zatrudnite za vrijeme uzimanja lijeka Klopidogrel HCS, odmah se posavjetujte s liječnikom jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor. 
1000 mg u 24 sata) općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
In a randomised, double-blind, parallel-group study (CLARINET), 906 paediatric patients (neonates and infants) with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt were randomised to receive clopidogrel 0.2 mg/kg (n=467) or placebo (n=439) along with concomitant background therapy up to the time of second stage surgery. 
U randomiziranoj, dvostrukoslijepoj studiji s paralelnim skupinama (CLARINET), 906 pedijatrijskih bolesnika (novorođenčad i dojenčad) s cijanotičnom kongenitalnom bolešću srca ublaženom sistemsko-plućnim arterijskim šantom, bilo je randomizirano u skupinu koje je primala klopidogrel u dozi od 0,2 mg/kg (n=467) ili placebo (n=439) zajedno s istodobnom popratnom terapijom sve do drugog operativnog zahvata.
Acetylsalicylic acid (ASA) 
Acetilsalicilatna kiselina (ASK)
Clopidogrel HCS contains hydrogenated castor oil 
Klopidogrel HCS sadrži hidrogenirano ricinusovo ulje
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Plavix and acetylsalicylic acid for this condition. 
Trebalo Vam je biti rečeno da su za ovo stanje 'oralni antikoagulansi' učinkovitiji od acetilsalicilatne kiseline ili kombinirane primjene lijeka
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers. 
Nisu opažene značajne razlike u izloženosti aktivnom metabolitu i prosječnoj vrijednosti inhibicije agregacije trombocita (IAT) između ultrabrzih, brzih i umjerenih metabolizatorima.
Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery. 
uključujući okultno krvarenje, i to poglavito tijekom prvih tjedana liječenja i/ili nakon invazivnih kardioloških postupaka ili kirurških zahvata.
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
U jednoj kliničkoj studiji provedenoj na zdravim dobrovoljcima, istodobna primjena klopidrogela i naproksena povećala je gubitak krvi okultnim krvarenjem iz probavnog trakta.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional. 
CYP2C19*1 alel odgovara potpuno funkcionalnom metabolizmu, dok su CYP2C19*2 i CYP2C19*3
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel HCS (4 tablets of 75 mg) once at the start of treatment. 
Ako ste imali jake bolove u prsištu (nestabilna angina ili srčani udar), liječnik Vam u početku liječenja može jednokratno dati 300 mg lijeka Klopidogrel HCS (4 tablete od po 75 mg).
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake. 
istodobna primjena 500 mg ASK dva puta na dan tijekom jednog dana nije značajno produljila vrijeme krvarenja već produljeno uzimanjem klopidogrela.
In a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation. 
U jednoj kliničkoj studiji provedenoj na zdravim ispitanicima, primjena klopidogrela nije iziskivala promjenu doze heparina, niti je mijenjala učinak heparina na koagulaciju.
Other concomitant therapy 
Ostala istodobna terapija
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers. 
Nakon režima doziranja od 300 mg/75 mg, antitrombocitni odgovor bio je smanjen u slabih metabolizatora sa srednjom vrijednosti IAT (5 μM ADP) od 24% (nakon 24 sata) te 37% (na dan 5), u usporedbi s vrijednostima IAT-e od 39% (24 sata) i 58% (dan 5) u brzih metabolizatora te 37% (24 sata) i 60% (dan 5) u umjerenih metabolizatora.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes. 
One su se javljale pri dozama koje su odgovarale barem 25 puta većoj od izloženosti od one u bolesnika koji su primali kliničku dozu od 75 mg klopidogrela na dan i bile su posljedice učinka na jetrene metaboličke enzime.
Other medicines and Clopidogrel HCS 
Drugi lijekovi i Klopidogrel HCS
If you forget to take a dose of Clopidogrel HCS, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Ako zaboravite uzeti jednu dozu lijeka Klopidogrel HCS, ali se toga sjetite u roku od 12 sati, odmah uzmite tabletu, a sljedeću tabletu uzmite u uobičajeno vrijeme.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = 
U bolesnika koji su u studiju uključeni samo zbog nedavnog infarkta miokarda, klopidogrel je bio brojčano slabiji, ali se statistički nije razlikovao od
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Zbog opasnosti od krvarenja i hematoloških nuspojava, potrebno je odmah provjeriti krvnu sliku i/ili druge relevantne nalaze kad god se tijekom liječenja pojave klinički znakovi koji ukazuju na krvarenje
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. 
Srednje vršne razine nepromijenjenog klopidogrela u plazmi (oko 2,2 - 2,5 ng/ml nakon jednokratne oralne doze od 75 mg), postižu se otprilike 45 minuta nakon uzimanja lijeka.
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots, and/or confusion (see section 2 ‘Warnings and precautions'). 
- znakove oštećenja funkcije jetre kao što su žuta boja kože ili očiju (žutica), bez obzira na to jesu li povezani s krvarenjem koje se pojavljuje kao crvene točkice ispod kože i/ili zbunjenošću (vidjeti dio 2 "Upozorenja i mjere opreza");
Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. 
Glavobolja, čir želuca, povraćanje, mučnina, zatvor, povećano stvaranje plinova u želucu ili crijevima, osip, svrbež, omaglica, osjećaj trnaca i utrnulosti.
Major bleeding was mostly of extracranial origin in both groups (5.3% in the clopidogrel + ASA group; 3.5% in the placebo +ASA group), mainly from the gastrointestinal tract (3.5% vs. 1.8%). 
Velika su krvarenja su najčešće bila ekstrakranijalnog porijekla u obje skupine (5,3% u skupini klopidogrel + ASK; 3,5% u skupini placebo + ASK), uglavnom iz probavnog trakta (3,5% naspram 1,8%).
HCS bvba H. Kennisstraat 53 B-2650 Edegem Belgium 
Kennisstraat 53 B-2650 Edegem Belgija
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised. 
Preporuča se nadzirati znakove preosjetljivosti u bolesnika s poznatom alergijom na tienopiridine
The most common side effect reported with Clopidogrel HCS is bleeding. 
Najčešća nuspojava lijeka Klopidogrel HCS jest krvarenje.
There was no significant difference between groups in the primary composite endpoint of death, shunt thrombosis or cardiac-related intervention prior to 120 days of age following an event considered of thrombotic nature (89 [19.1%] for the clopidogrel group and 90 [20.5%] for the placebo group) (see section 4.2). 
Nije bilo značajne razlike među skupinama u primarnom kompozitnom ishodu koji se odnosi na smrt, trombozu šanta ili kardiološku intervenciju prije 120-og dana starosti nakon događaja za koji se smatra da je trombološke prirode (89 [19,1%] za klopidogrel skupinu i 90 [20,5%]
When poor metabolisers received the 600 mg/150 mg regimen, active metabolite exposure was greater than with the 300 mg/75 mg regimen. 
600 mg/150 mg, izloženost aktivnom metabolitu bila je veća nego kod režima doziranja od
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
U skladu s gore navedenim rezultatima, metaanaliza koja je uključivala 6 studija sa 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazala je da je izloženost aktivnom metabolitu smanjena za 28% u umjerenih metabolizatora te za 72% u slabih metabolizatora, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena uz razlike u vrijednosti IAT-e od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Plavix. 
Ako ste trudni ili sumnjate na trudnoću, obavijestite svog liječnika ili ljekarnika prije nego što uzmete
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel HCS per day to be taken orally with or without food, and at the same time each day. 
Preporučena doza, uključujući za bolesnike sa stanjem zvanim "fibrilacija atrija" (nepravilni otkucaji srca), je jedna tableta Klopidogrela HCS od 75 mg dnevno koja se uzima kroz usta, s obrokom ili bez obroka, i u isto vrijeme svaki dan.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age ≥75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease. 
Bolesnici randomizirani u programu ACTIVE imali su dokumentiranu fibrilaciju atrija (FA), tj. ili permanentnu FA ili najmanje 2 epizode intermitentne FA u zadnjih 6 mjeseci te su imali najmanje jedan od sljedećih faktora rizika: dob ≥75 godina ili 55 do 74 godine te ili dijabetes koji zahtijeva terapiju lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; ako su primali terapiju za sistemsku hipertenziju; prethodni moždani udar, prolazni ishemijski napadaj (TIA) ili ne-CNS sistemska embolija; disfunkcija lijevog ventrikula s ejekcijskom frakcijom lijevog ventrikula <45% ili dokumentirana periferna vaskularna bolest.
Clopidogrel HCS is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Klopidogrel HCS uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. 
U studiji CURE, u kojoj je klopidogrel primjenjivan istodobno s ASK nije bilo povećanja broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.